INTELLECTUAL PROPERTY
Aduro’s intellectual property portfolio includes a number of issued patents, both in the United States (see below) and in various foreign countries, related to our proprietary Listeria platform. Our intellectual property includes patents and patent applications directed to methods for attenuating the Listeria bacterium to improve its safety in vaccine formulations; methods for expression of disease-related antigens for therapeutic and prophylactic purposes; nucleic acid constructs; and the vaccine bacteria themselves. We have also entered into a number of strategic licensing arrangements with both universities and commercial entities that augment our own patent portfolio and enhance our ability to develop our proprietary Listeria platform.
Issued U.S. Patents:
•
7,935,804 (issued May 3, 2011)
•
7,927,606 (issued April 19, 2011)
•
7,842,289 (issued November 30, 2010)
•
7,833,775 (issued November 16, 2010)
•
7,695,725 (issued April 13, 2010)
•
7,691,393 (issued April 6, 2010)